What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025BloodOpen Access

Durable responses in patients with large B-cell lymphoma and 3+ prior lines of therapy who either paused or discontinued epcoritamab monotherapy while in complete response

View Full Paper

Ask AI

Bookmark

Authors

CCChan Y. CheahThe University of Western Australia JJJieying JiangAbbVie (United States)MAMohammad AtiyaGenmab (United States)

Discussion

Member takes

Implication

Analysis reveals treatment discontinuation does not diminish durable responses in large B-cell lymphoma, suggesting potential flexibility of epcoritamab therapy.

Key Points

Patients with large B-cell lymphoma maintained durable responses despite treatment discontinuation.
The median progression-free survival was reported as not reached (NR) amidst adverse events during treatment.
Analysis of treatment pauses and discontinuation in patients showed ongoing complete responses, with some achieving over 3 years.
Continued monitoring and assessment of epcoritamab can support personalized treatment strategies.

Cite This Study

Cheah et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d519 https://doi.org/10.1182/blood-2025-5511

View Full Paper

Ask AI

Bookmark

Implication

Analysis reveals treatment discontinuation does not diminish durable responses in large B-cell lymphoma, suggesting potential flexibility of epcoritamab therapy.

Durable responses in patients with large B-cell lymphoma and 3+ prior lines of therapy who either paused or discontinued epcoritamab monotherapy while in complete response

Discussion

Member takes

Implication

Key Points

Cite This Study

Durable responses in patients with large B-cell lymphoma and 3+ prior lines of therapy who either paused or discontinued epcoritamab monotherapy while in complete response

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider